Sofinnova closes second crossover fund at €725M for late-stage European biotechs
Sofinnova Partners has secured €725 million ($815 million) for its second crossover fund, which it said would fill the financing gap for late-stage European biopharma and medtech companies. Europe has the science and the companies ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.